Ultragenyx Cuts 10% of Workforce, Targets Profitability in 2027

Dow Jones

Feb 13

By Elias Schisgall

Ultragenyx Pharmaceutical will lay off 10% of its workforce, roughly 130 employees, as part of a strategic restructuring plan.

The biopharmaceutical company said Thursday that the reorganization is designed to support a path to profitability by 2027. It expects to take a roughly $50 million charge in 2026 related to severance, manufacturing, and other non-recurring restructuring charges.

The company reported a fourth-quarter loss of $129 million, or $1.29 a share, compared with a loss of $133 million, or $1.39 a share, a year earlier. Analysts polled by FactSet were expecting a loss of $1.09 a share.

Revenue rose to $207 million, up from $165 million a year earlier. Analysts were expecting $198.6 million in revenue.

For the current year, Ultragenyx is expecting revenue between $730 million and $760 million, excluding revenue from new product launches.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

February 12, 2026 17:14 ET (22:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611905664"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611905664\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611905664?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 06:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611905664","market":"fut","top_or_hot":-1,"title":"Ultragenyx Cuts 10% of Workforce, Targets Profitability in 2027","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ultragenyx Pharmaceutical will lay off 10% of its workforce, roughly 130 employees, as part of a strategic restructuring plan. \n</p>\n<p>\n  The biopharmaceutical company said Thursday that the reorganization is designed to support a path to profitability by 2027. It expects to take a roughly $50 million charge in 2026 related to severance, manufacturing, and other non-recurring restructuring charges. \n</p>\n<p>\n  The company reported a fourth-quarter loss of $129 million, or $1.29 a share, compared with a loss of $133 million, or $1.39 a share, a year earlier. Analysts polled by FactSet were expecting a loss of $1.09 a share. \n</p>\n<p>\n  Revenue rose to $207 million, up from $165 million a year earlier. Analysts were expecting $198.6 million in revenue. \n</p>\n<p>\n  For the current year, Ultragenyx is expecting revenue between $730 million and $760 million, excluding revenue from new product launches. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2026 17:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx Cuts 10% of Workforce, Targets Profitability in 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx Cuts 10% of Workforce, Targets Profitability in 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-13 06:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ultragenyx Pharmaceutical will lay off 10% of its workforce, roughly 130 employees, as part of a strategic restructuring plan. \n</p>\n<p>\n  The biopharmaceutical company said Thursday that the reorganization is designed to support a path to profitability by 2027. It expects to take a roughly $50 million charge in 2026 related to severance, manufacturing, and other non-recurring restructuring charges. \n</p>\n<p>\n  The company reported a fourth-quarter loss of $129 million, or $1.29 a share, compared with a loss of $133 million, or $1.39 a share, a year earlier. Analysts polled by FactSet were expecting a loss of $1.09 a share. \n</p>\n<p>\n  Revenue rose to $207 million, up from $165 million a year earlier. Analysts were expecting $198.6 million in revenue. \n</p>\n<p>\n  For the current year, Ultragenyx is expecting revenue between $730 million and $760 million, excluding revenue from new product launches. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2026 17:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2611905664","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611905664","pubTimestamp":1770934440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ultragenyx Pharmaceutical will lay off 10% of its workforce, roughly 130 employees, as part of a strategic restructuring plan.The biopharmaceutical company said Thursday that the reorganization is designed to support a path to profitability by 2027. It expects to take a roughly $50 million charge in 2026 related to severance, manufacturing, and other non-recurring restructuring charges.The company reported a fourth-quarter loss of $129 million, or $1.29 a share, compared with a loss of $133 million, or $1.39 a share, a year earlier. Analysts polled by FactSet were expecting a loss of $1.09 a share.Revenue rose to $207 million, up from $165 million a year earlier. Analysts were expecting $198.6 million in revenue.For the current year, Ultragenyx is expecting revenue between $730 million and $760 million, excluding revenue from new product launches.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc","BK4139":"生物科技"},"translate_title":"Ultragenyx裁员10%，目标2027年实现盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Ultragenyx Pharmaceutical will lay off 10% of its workforce, roughly 130 employees, as part of a strategic restructuring plan. \n\n\n  The biopharmaceutical company said Thursday that the reorganization is designed to support a path to profitability by 2027. It expects to take a roughly $50 million charge in 2026 related to severance, manufacturing, and other non-recurring restructuring charges. \n\n\n  The company reported a fourth-quarter loss of $129 million, or $1.29 a share, compared with a loss of $133 million, or $1.39 a share, a year earlier. Analysts polled by FactSet were expecting a loss of $1.09 a share. \n\n\n  Revenue rose to $207 million, up from $165 million a year earlier. Analysts were expecting $198.6 million in revenue. \n\n\n  For the current year, Ultragenyx is expecting revenue between $730 million and $760 million, excluding revenue from new product launches. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2026 17:14 ET (22:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}